Get Medicare Drug Money Totals
drug_money_summaryTotals from the Medicare Drug Money Register, built from CMS's Part D and Part B spending files, CMS's negotiated-price file and fact sheets, the Federal Register, the White House's fact sheets and annexes, and, side by side, FEC, LDA and two MORVS registers' records. Returns Medicare Part D gross drug cost for all drugs by year (annual and preliminary kept apart), the 10 largest parent companies with their shares and the cost not rolled up to any parent, by class; the share of Part D gross drug cost in the earliest preliminary year held by the companies the White House listed (computed here from CMS's file, labelled as such); the negotiated drugs' gross cost per prescription in the register's baseline and latest preliminary periods by cycle, each beside CMS's net estimate or the stated absence of one, with the drugs outside CMS's band flagged as the register flags them; Proclamation 11020's ad valorem duty rates and the zero rate for companies with pricing agreements, as printed; CMS's GLOBE estimates proposed and final, like for like, and its GUARD and GENEROUS estimates; Part B drug spending without skin substitutes, and skin-substitute totals; the counter-findings; the register's headlines with their basis; and what is excluded (pharmacy benefit managers, plan sponsors, cash prices, Medicaid by drug) and withheld (counts only). Each figure is named in its record's own words: "gross drug cost" (CMS), CMS's negotiated prices ("negotiated prices, which the statute refers to as maximum fair prices"), "announced an agreement" (the White House), "ad valorem duty rate" (the proclamation) and CMS's "estimated savings". Gross is never net: gross drug cost is before manufacturers' rebates, which CMS may not publish, so a lower gross cost per prescription is never called a saving; CMS's own net estimate is shown beside every claims-based price figure, or the answer says that CMS gives none. Annual years come from CMS's annual file; the later periods come from its preliminary quarterly file, are labelled preliminary and are never put in one series with the annual years. The blocks (Part D gross drug cost by company, negotiated prices and the negotiated drugs' claims, the 2025-26 agreements, tariffs and CMS's payment models, Part B drug spending, and skin substitutes as totals only) are never added together. The side columns (connected-PAC money from the FEC bulk files, 2025 lobbying reports from lda.gov, the 2025 inaugural committee's report and its LD-203 cross-check, and super PAC membership) are separate records shown side by side: never added to drug cost or to each other, and never put in date sequence with an agreement, a tariff or a price. Every answer carries the register's question note: these records show Medicare's gross drug costs as CMS reports them, CMS's negotiated prices and estimates, and the government's announcements and proclamations; they do not show rebates paid, what any company agreed to beyond the published texts, or why any price or agreement was set. Every answer also carries the side-by-side caption, the as-of date, each file's date, the source page on morvs.ai and the data's licence. Where FEC figures appear, the answer quotes the FEC's restriction on the sale or use of individual contributor information (52 U.S.C. 30111(a)(4)). Institutions only: no prescriber, physician, official, signer or member of Congress is named; labeler strings that read as a person's name are withheld and appear only as counts. No party label is given.
Input Schema
| Name | Required | Description | Default |
|---|---|---|---|
No arguments | |||